| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10964737 | Vaccine | 2014 | 9 Pages |
Abstract
By adopting WHO's classification that an intervention is cost-effective if ICER (in QALY) is between one and three times of GDP as a criterion, either of the vaccination programme is concluded as cost-effective from payer's or societal perspectives. Likewise, to uptake second dose at 3-5 years old is more favourable than an uptake at any other age because of lower incremental cost-effectiveness ratios.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Shu-ling Hoshi, Masahide Kondo, Ichiro Okubo,